Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Netherlands
  4. Euronext Amsterdam
  5. Galapagos NV
  6. News
  7. Summary
    GLPG   BE0003818359

GALAPAGOS NV

(GLPG)
  Report
Real-time Euronext Amsterdam  -  11:35 2022-09-27 am EDT
44.49 EUR   +0.18%
09/09Morgan Stanley Downgrades Galapagos to Equalweight From Overweight, Cuts Price Target to $61 From $80
MT
08/29Galapagos receives transparency notification from FMR LLC
GL
08/29Galapagos receives transparency notification from FMR LLC
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Galapagos : receives transparency notification from FMR LLC - Form 6-K

08/09/2022 | 07:06am EDT

Galapagos receives transparency notification from FMR LLC

Mechelen, Belgium;8 August 2022, 22.01CET;regulated information - Galapagos NV (Euronext & NASDAQ: GLPG) received a transparency notification from FMR LLC.

Pursuant to Belgian transparency legislation1, Galapagos received a transparency notification on 3 August 2022 from FMR LLC, who notified that it holds 3,739,645 of Galapagos' voting rights, consisting of ordinary shares (3,707,145) and equivalent financial instruments (32,500). FMR LLC controls investment funds FIAM Holdings LLC, Fidelity Management & Research Company LLC, Fidelity Management Trust Company and Strategic Advisers LLC, of which Fidelity Management & Research Company LLC increased its position to 3,300,782 voting rights, consisting of ordinary shares (3,268,282) and equivalent financial instruments (32,500), representing 5.02% of Galapagos' currently outstanding shares. Hence, this controlled undertaking of FMR LLC group individually crossed the 5% threshold. FMR LLC's holding of 3,739,645 Galapagos' voting rights now represents 5.69% of Galapagos' currently outstanding 65,728,511 shares. FMR LLC thus remains above the 5% threshold of Galapagos' voting rights by acquisition of voting securities on 29 July 2022. The full transparency notice is available on the Galapagos website.

About Galapagos
Galapagos is a fully integrated biotechnology company focused on discovering, developing, and commercializing innovative medicines. We are committed to improving patients' lives worldwide by targeting diseases with high unmet needs. Our R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Our portfolio comprises discovery through to Phase 3 programs in inflammation, oncology, fibrosis, and other indications. Our first medicine for rheumatoid arthritis and ulcerative colitis is approved and available in the European Union (including Norway), Great Britain and Japan. For additional information, please visit www.glpg.com or follow us on LinkedIn or Twitter.

Contact
Investors:
Sofie Van Gijsel
Head of Investor Relations
+1 781 296 1143

Sandra Cauwenberghs
Director Investor Relations
+32 495 58 46 63
ir@glpg.com

Media:
Marieke Vermeersch
Head of Corporate Communication
+32 479 490 603
media@glpg.com

1 Belgian Act of 2 May 2007 on the disclosure of major shareholdings in issuers whose shares are admitted to trading on a regulated market



Disclaimer

Galapagos NV published this content on 09 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 August 2022 11:05:00 UTC.


© Publicnow 2022
All news about GALAPAGOS NV
09/09Morgan Stanley Downgrades Galapagos to Equalweight From Overweight, Cuts Price Target t..
MT
08/29Galapagos receives transparency notification from FMR LLC
GL
08/29Galapagos receives transparency notification from FMR LLC
AQ
08/29GALAPAGOS NV : Threshold crossings
CO
08/24Galapagos to present at upcoming investor conferences
GL
08/24Galapagos to present at upcoming investor conferences
AQ
08/19Galapagos : receives transparency notification from FMR LLC - Form 6-K
PU
08/18Galapagos receives transparency notification from FMR LLC
GL
08/18Galapagos receives transparency notification from FMR LLC
AQ
08/15Morgan Stanley Raises Galapagos NV's Price Target to $80 From $79, Maintains Overweight..
MT
More news
Analyst Recommendations on GALAPAGOS NV
More recommendations
Financials
Sales 2022 536 M 517 M 517 M
Net income 2022 -148 M -143 M -143 M
Net cash 2022 3 502 M 3 378 M 3 378 M
P/E ratio 2022 -26,1x
Yield 2022 -
Capitalization 2 919 M 2 802 M 2 816 M
EV / Sales 2022 -1,09x
EV / Sales 2023 -0,57x
Nbr of Employees 1 344
Free-Float 73,7%
Chart GALAPAGOS NV
Duration : Period :
Galapagos NV Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GALAPAGOS NV
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 7
Last Close Price 44,41 €
Average target price 59,29 €
Spread / Average Target 33,5%
EPS Revisions
Managers and Directors
Paulus Stoffels Chairman & Chief Executive Officer
Bart Filius President, Chief Operating & Financial Officer
Walid Abi-Saab Chief Medical Officer
Howard Mitchell Rowe Independent Non-Executive Director
Katrine S. Bosley Independent Non-Executive Director
Sector and Competitors
1st jan.Capi. (M$)
GALAPAGOS NV-9.77%2 816
MODERNA, INC.-52.87%46 823
IQVIA HOLDINGS INC.-34.05%34 705
LONZA GROUP AG-42.20%32 942
SEAGEN INC.-12.50%24 949
ALNYLAM PHARMACEUTICALS, INC.18.40%23 692